Business Context and Reporting Period
Priveterra Acquisition Corp. filed this Form 8-K on June 9, 2023, regarding its proposed business combination with AEON Biopharma, Inc. The filing supplements the definitive proxy statement filed May 12, 2023. It is not an AEON Biopharma operating or financial results filing.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, valuation, or other operating financial metrics.
Material Changes
- The special meeting originally scheduled for June 9, 2023, was adjourned to June 13, 2023, at 12:00 p.m. Eastern Time.
- The adjournment was intended to allow additional time for Priveterra to engage with stockholders.
- The meeting location, April 11, 2023 record date, redemption deadline, and other proposals were unchanged.
- Stockholders who previously voted and do not wish to change their vote need not take further action.
- Stockholders wishing to withdraw redemption requests could do so before the rescheduled meeting by requesting return of their shares from the transfer agent.
Outlook, Risks, and Unusual Items
The proposed AEON transaction remained subject to stockholder approval and related transaction conditions. The filing contains customary forward-looking statement warnings, including risks and uncertainties described in the proxy statement, related registration statement, and other SEC filings. No new financial guidance or operating outlook was provided.
Investor Verification Items
- Verify the outcome of the adjourned June 13, 2023 special meeting and the vote on the business combination proposal.
- Review redemption levels, available transaction proceeds, and any financing arrangements in subsequent filings.
- Review the definitive proxy statement and related registration statement for transaction terms, dilution, AEON financial information, and risk factors.
- Confirm whether and when the business combination closed and whether the combined company adopted AEON Biopharma’s name and trading symbols.